Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation
Edited by David Baker, University of Washington, Seattle, WA, and approved September 26, 2013 (received for review July 29, 2013)
Significance
Trimeric forms of HIV-1 envelope glycoproteins are being used for structural and vaccine studies. The most common way to make these proteins is to eliminate the cleavage site between the glycoprotein (gp)120 and gp41 subunits. We show that doing so creates trimers that adopt irregular, nonnative configurations. Cleaved, stabilized trimers, in contrast, resemble the native spikes on the HIV-1 virus. Our findings will help structural and vaccine programs by showing how to make native-like trimers. The rationale for vaccine trials based on the use of uncleaved gp140 trimers should be reevaluated.
Abstract
We compare the antigenicity and conformation of soluble, cleaved vs. uncleaved envelope glycoprotein (Env gp)140 trimers from the subtype A HIV type 1 (HIV-1) strain BG505. The impact of gp120–gp41 cleavage on trimer structure, in the presence or absence of trimer-stabilizing modifications (i.e., a gp120–gp41 disulfide bond and an I559P gp41 change, together designated SOSIP), was assessed. Without SOSIP changes, cleaved trimers disintegrate into their gp120 and gp41-ectodomain (gp41ECTO) components; when only the disulfide bond is present, they dissociate into gp140 monomers. Uncleaved gp140s remain trimeric whether SOSIP substitutions are present or not. However, negative-stain electron microscopy reveals that only cleaved trimers form homogeneous structures resembling native Env spikes on virus particles. In contrast, uncleaved trimers are highly heterogeneous, adopting a variety of irregular shapes, many of which appear to be gp120 subunits dangling from a central core that is presumably a trimeric form of gp41ECTO. Antigenicity studies with neutralizing and nonneutralizing antibodies are consistent with the EM images; cleaved, SOSIP-stabilized trimers express quaternary structure-dependent epitopes, whereas uncleaved trimers expose nonneutralizing gp120 and gp41ECTO epitopes that are occluded on cleaved trimers. These findings have adverse implications for using soluble, uncleaved trimers for structural studies, and the rationale for testing uncleaved trimers as vaccine candidates also needs to be reevaluated.
Acknowledgments
We are grateful to D. R. Burton, J. Mascola, and P. D. Kwong for reagents. This work was supported by National Institutes of Health (NIH) Grants P01 AI82362, R37 AI36082, and R01 AI84817; Aids Fonds Netherlands Grant 2011032; and the International AIDS Vaccine Initiative. J.-P.J. has a CIH Research Fellowship. R.W.S. has a Netherlands Organization for Scientific Research Vidi Grant and a Starting Investigator Grant (ERC-StG-2011–280829-SHEV). EM data were collected at the National Resource for Automated Molecular Microscopy at The Scripps Research Institute, supported by NIH Grant P41 RR017573.
Supporting Information
Supporting Information (PDF)
Supporting Information
- Download
- 918.18 KB
References
1
GB Melikyan, Common principles and intermediates of viral protein-mediated fusion: The HIV-1 paradigm. Retrovirology 5, 111 (2008).
2
PJ Klasse, The molecular basis of HIV entry. Cell Microbiol 14, 1183–1192 (2012).
3
MB Zwick, DR Burton, HIV-1 neutralization: Mechanisms and relevance to vaccine design. Curr HIV Res 5, 608–624 (2007).
4
LM Walker, DR Burton, Rational antibody-based HIV-1 vaccine design: Current approaches and future directions. Curr Opin Immunol 22, 358–366 (2010).
5
MA Checkley, BG Luttge, EO Freed, HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 410, 582–608 (2011).
6
J Liu, A Bartesaghi, MJ Borgnia, G Sapiro, S Subramaniam, Molecular architecture of native HIV-1 gp120 trimers. Nature 455, 109–113 (2008).
7
PL Earl, et al., Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 68, 3015–3026 (1994).
8
F Gao, et al., Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J Virol 79, 1154–1163 (2005).
9
P Spearman, et al., A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis; HIV Vaccine Trials Network of NIAID 203, 1165–1173 (2011).
10
X Yang, R Wyatt, J Sodroski, Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 75, 1165–1171 (2001).
11
X Yang, et al., Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 76, 4634–4642 (2002).
12
JM Kovacs, et al., HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci USA 109, 12111–12116 (2012).
13
JM Binley, et al., A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74, 627–643 (2000).
14
RW Sanders, et al., Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76, 8875–8889 (2002).
15
JM Binley, et al., Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 76, 2606–2616 (2002).
16
S Beddows, et al., A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360, 329–340 (2007).
17
RW Sanders, et al., A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 9, e1003618 (2013).
18
JP Julien, et al., Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci USA 110, 4351–4356 (2013).
19
JP Julien, et al., Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 9, e1003342 (2013).
20
RW Sanders, Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine. Expert Rev Vaccines 10, 1117–1120 (2011).
21
Y Morikawa, E Barsov, I Jones, Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin. J Virol 67, 3601–3604 (1993).
22
RJ Center, J Lebowitz, RD Leapman, B Moss, Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras. J Virol 78, 2265–2276 (2004).
23
PJ Klasse, et al., Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol 87, 9873–9885 (2013).
24
R Khayat, et al., Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol 87, 9865–9872 (2013).
25
T Schiffner, et al., Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. J Virol 87, 10163–10172 (2013).
26
Z Si, N Phan, E Kiprilov, J Sodroski, Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res Hum Retroviruses 19, 217–226 (2003).
27
M Pancera, R Wyatt, Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332, 145–156 (2005).
28
T Tong, K Osawa, JE Robinson, ET Crooks, JM Binley, Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120. J Virol 87, 9233–9249 (2013).
29
JM Binley, et al., Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol 77, 5678–5684 (2003).
30
RW Sanders, E Busser, JP Moore, M Lu, B Berkhout, Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS Res Hum Retroviruses 20, 742–749 (2004).
31
M Guttman, KK Lee, A functional gp41-gp120 interaction is observed in monomeric but not oligomeric, uncleaved HIV-1 Env gp140. J Virol 87, 11462–11475 (August 21, 2013).
32
E Helseth, U Olshevsky, C Furman, J Sodroski, Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol 65, 2119–2123 (1991).
33
G Ferrari, et al., An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 85, 7029–7036 (2011).
34
PW Parren, et al., Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol 72, 3512–3519 (1998).
35
D Lyumkis, et al., Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 Env trimer. Science, in press. (2013).
36
JP Julien, et al., Crystal structure of a soluble cleaved HIV-1 envelope trimer in complex with a glycan-dependent broadly neutralizing antibody. Science, in press. (2013).
Information & Authors
Information
Published in
Classifications
Submission history
Published online: October 21, 2013
Published in issue: November 5, 2013
Acknowledgments
We are grateful to D. R. Burton, J. Mascola, and P. D. Kwong for reagents. This work was supported by National Institutes of Health (NIH) Grants P01 AI82362, R37 AI36082, and R01 AI84817; Aids Fonds Netherlands Grant 2011032; and the International AIDS Vaccine Initiative. J.-P.J. has a CIH Research Fellowship. R.W.S. has a Netherlands Organization for Scientific Research Vidi Grant and a Starting Investigator Grant (ERC-StG-2011–280829-SHEV). EM data were collected at the National Resource for Automated Molecular Microscopy at The Scripps Research Institute, supported by NIH Grant P41 RR017573.
Notes
This article is a PNAS Direct Submission.
Authors
Competing Interests
Conflict of interest statement: R.W.S., A.C., J.-P.J., I.A.W., P.J.K., A.B.W., and J.P.M. are listed on a patent application relating to the design and use of soluble, cleaved envelope glycoprotein trimers.
Metrics & Citations
Metrics
Altmetrics
Citations
Cite this article
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation, Proc. Natl. Acad. Sci. U.S.A.
110 (45) 18256-18261,
https://doi.org/10.1073/pnas.1314351110
(2013).
Copied!
Copying failed.
Export the article citation data by selecting a format from the list below and clicking Export.
Cited by
Loading...
View Options
View options
PDF format
Download this article as a PDF file
DOWNLOAD PDFLogin options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginRecommend to a librarian
Recommend PNAS to a LibrarianPurchase options
Purchase this article to access the full text.